As mentioned before, Bcl-2 inhibitors have been used in various hematologic malignancies, mainly in combination with other chemotherapies, with promising results for patients’ survival, which led to their approval by the FDA and EMA for these types of neoplasms [28,46,47,66,67,68]. The gene discussed is BCL2; the disease is neoplasm.